Ideaya Biosciences Inc

+0.60 (+2.42%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)998.25M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.55 Million
Adjusted EPS-$0.30
See more estimates
10-Day MA$25.82
50-Day MA$24.06
200-Day MA$20.47
See more pivots

Ideaya Biosciences Inc Stock, NASDAQ:IDYA

7000 Shoreline Court, Suite 350, South San Francisco, California 94080
United States of America
Phone: +1.650.443.6209
Number of Employees: 62


IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.